Official Positions for FRAX® Clinical Regarding Glucocorticoids: The Impact of the Use of Glucocorticoids on the Estimate by FRAX® of the 10 Year Risk of Fracture

被引:55
|
作者
Leib, Edward S. [1 ]
Saag, Kenneth G. [2 ]
Adachi, Jonathan D. [3 ]
Geusens, Piet P. [4 ,5 ]
Binkley, Neil [6 ]
McCloskey, Eugene V. [7 ]
Hans, Didier B. [8 ]
机构
[1] Univ Vermont, Coll Med, Burlington, VT 05401 USA
[2] Univ Alabama Birmingham, Birmingham, AL USA
[3] McMaster Univ, St Josephs Healthcare, Hamilton, ON, Canada
[4] Maastricht Univ Caphri, Dept Internal Med, Fac Hlth Med & Life Sci, Maastricht, Netherlands
[5] Univ Hasselt, Biomed Res Ctr, Hasselt, Belgium
[6] Univ Wisconsin, Sch Med & Publ Hlth, Madison, WI USA
[7] Univ Sheffield, Sheffield, S Yorkshire, England
[8] Univ Lausanne Hosp, Dept Bone & Joint, Lausanne, Switzerland
基金
英国医学研究理事会;
关键词
Glucocorticoids; fracture risk; drug-induced osteoporosis; FRAX; BONE-MINERAL DENSITY; OBSTRUCTIVE PULMONARY-DISEASE; LOW-DOSE PREDNISONE; INHALED CORTICOSTEROIDS; ADDISONS-DISEASE; REPLACEMENT THERAPY; 21-HYDROXYLASE DEFICIENCY; INDUCED OSTEOPOROSIS; ORAL GLUCOCORTICOIDS; RHEUMATOID-ARTHRITIS;
D O I
10.1016/j.jocd.2011.05.014
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Given the significant impact the use of glucocorticoids can have on fracture risk independent of bone density, their use has been incorporated as one of the clinical risk factors for calculating the 10-year fracture risk in the World Health Organization's Fracture Risk Assessment Tool (FRAX (R)). Like the other clinical risk factors, the use of glucocorticoids is included as a dichotomous variable with use of steroids defined as past or present exposure of 3 months or more of use of a daily dose of 5 mg or more of prednisolone or equivalent. The purpose of this report is to give clinicians guidance on adjustments which should be made to the 10-year risk based on the dose, duration of use and mode of delivery of glucocorticoid preparations. A subcommittee of the International Society for Clinical Densitometry and International Osteoporosis Foundation joint Position Development Conference presented its findings to an expert panel and the following recommendations were selected. 1) There is a dose relationship between glucocorticoid use of greater than 3 months and fracture risk. The average dose exposure captured within FRAX (R) is likely to be a prednisone dose of 2.5-7.5 mg/day or its equivalent. Fracture probability is under-estimated when prednisone dose is greater than 7.5 mg/day and is over-estimated when the prednisone dose is less than 2.5 mg/day. 2) Frequent intermittent use of higher doses of glucocorticoids increases fracture risk. Because of the variability in dose and dosing schedule, quantification of this risk is not possible. 3) High dose inhaled glucocorticoids may be a risk factor for fracture. FRAX (R) may underestimate fracture probability in users of high dose inhaled glucocorticoids. 4) Appropriate glucocorticoid replacement in individuals with adrenal insufficiency has not been found to increase fracture risk. In such patients, use of glucocorticoids should not be included in FRAX (R) calculations.
引用
收藏
页码:212 / 219
页数:8
相关论文
共 50 条
  • [21] Assessment of the 10-year risk of fracture in Italian postmenopausal women using FRAX®: A north Italian multicenter study
    Pedrazzoni, M.
    Girasole, G.
    Giusti, A.
    Barone, A.
    Pioli, G.
    Passeri, G.
    Palummeri, E.
    Bianchi, G.
    JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION, 2011, 34 (11) : E386 - E391
  • [22] Limitations of Estimated FRAX® 10-Year Fracture Risk at the Time of Incident Fracture and Upon Refracture: Results from the OPTIMUS Initiative
    April, Pierre-Marc
    Cabana, Francois
    Roux, Sophie
    Beaulieu, Marie-Claude
    Beaulieu, Michele
    Boire, Gilles
    JOURNAL OF RHEUMATOLOGY, 2013, 40 (06) : 1009 - 1010
  • [23] The association between 10-year fracture risk by FRAX and osteoporotic fractures with disease activity in patients with rheumatoid arthritis
    Ratanapha Phuan-udom
    Nittaya Lektrakul
    Wanruchada Katchamart
    Clinical Rheumatology, 2018, 37 : 2603 - 2610
  • [24] The association between 10-year fracture risk by FRAX and osteoporotic fractures with disease activity in patients with rheumatoid arthritis
    Phuan-udom, Ratanapha
    Lektrakul, Nittaya
    Katchamart, Wanruchada
    CLINICAL RHEUMATOLOGY, 2018, 37 (10) : 2603 - 2610
  • [25] Correlation between FRAX UK with and without Bone Mineral Density (BMD) in predicting the 10-year fracture risk
    Obiechina, N.
    Michael, A.
    Nandi, A.
    Jameel, I.
    Ali, U.
    Subramaniam, N.
    Iqbal, I. I.
    JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 2021, 69 : S142 - S143
  • [26] Simple models predicted 10-year fracture risk in older women as accurately as more complex FRAX models
    Kauffman, Robert P.
    ANNALS OF INTERNAL MEDICINE, 2010, 152 (06)
  • [27] Assessment of the 10-year risk of fracture in Italian postmenopausal women using FRAX®: A north Italian multicenter study
    M. Pedrazzoni
    G. Girasole
    A. Giusti
    A. Barone
    G. Pioli
    G. Passeri
    E. Palummeri
    G. Bianchi
    Journal of Endocrinological Investigation, 2011, 34 : e386 - e391
  • [28] TEN-YEAR FRACTURE RISK ASSESSMENT USING A COMPUTERIZED ALGORITHM (FRAX((R))). USES AND LIMITATIONS IN CLINICAL PRACTICE
    Wiluzanski, Diana
    ACTUALIZACIONES EN OSTEOLOGIA, 2013, 9 (03) : 241 - 244
  • [29] FREM Affects Incident 10-year Fracture Risk Independent of FRAX® Probability: A Registry-Based Cohort Study
    Leslie, William
    Moller, Soren
    Skjodt, Michael
    Yan, Lin
    Abrahamsen, Bo
    Lix, Lisa
    McCloskey, Eugene
    Johansson, Helena
    Harvey, Nicholas
    Kanis, John
    Rubin, Katrine
    JOURNAL OF BONE AND MINERAL RESEARCH, 2022, 37 : 305 - 306
  • [30] FREM predicts 10-year incident fracture risk independent of FRAX® probability: a registry-based cohort study
    William D. Leslie
    Sören Möller
    Michael K. Skjødt
    Lin Yan
    Bo Abrahamsen
    Lisa M. Lix
    Eugene V. McCloskey
    Helena Johansson
    Nicholas C. Harvey
    John A. Kanis
    Katrine Hass Rubin
    Osteoporosis International, 2022, 33 : 1457 - 1463